News Digest / Ticker: IMVT

Ticker: IMVT

08:07am, Monday, Aug 11, 2025

Immunovant ramps IMVT‑1402 trials, burns cash but has $599M runway to 2027 GD readout

Immunovant, Inc. (NASDAQ: IMVT) - Quick internal update What's happening inside: management is aggressively advancing its next‑generation FcRn candidate IMVT‑1402 across multiple potentially registrational programs while maintaining batoclimab development with partner HanAll. The company is burni...